Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 41 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 26% bearish. Among these notable options, 27 are puts, totaling $1,787,322, and 14 are calls, amounting to $807,770.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $520.0 to $950.0 for Eli Lilly over the last 3 months.
Insights into Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 358.06 with a total volume of 1,100.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $520.0 to $950.0 over the last 30 days.
Eli Lilly Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | PUT | TRADE | NEUTRAL | 01/16/26 | $57.7 | $52.75 | $55.5 | $650.00 | $416.2K | 153 | 77 |
| LLY | CALL | TRADE | BULLISH | 07/18/25 | $44.15 | $41.2 | $43.0 | $850.00 | $129.0K | 0 | 20 |
| LLY | PUT | SWEEP | BULLISH | 04/17/25 | $59.5 | $57.1 | $57.1 | $720.00 | $119.9K | 211 | 23 |
| LLY | PUT | TRADE | NEUTRAL | 02/21/25 | $233.5 | $226.4 | $229.83 | $950.00 | $114.9K | 66 | 0 |
| LLY | PUT | SWEEP | BEARISH | 03/21/25 | $71.85 | $70.2 | $70.2 | $750.00 | $112.3K | 200 | 19 |
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly's Current Market Status
- With a trading volume of 1,880,416, the price of LLY is down by -0.65%, reaching $722.49.
- Current RSI values indicate that the stock is may be oversold.
- Next earnings report is scheduled for 77 days from now.
What The Experts Say On Eli Lilly
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1068.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Eli Lilly, targeting a price of $975. * An analyst from B of A Securities has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1100. * An analyst from Wolfe Research has revised its rating downward to Outperform, adjusting the price target to $1000. * An analyst from Citigroup has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1250. * An analyst from Deutsche Bank has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1015.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
